These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28883226)

  • 21. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
    Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
    Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory issues facing the development of drug-eluting stents: a US FDA perspective.
    Boam AB
    Expert Rev Med Devices; 2006 May; 3(3):297-300. PubMed ID: 16681451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronary disease and non-ST-elevation acute coronary syndrome.
    Kong DF; Saito S; Nakamura S; Mehran R; Rowland SM; Handler A; Al-Khalidi HR; Krucoff MW
    Am Heart J; 2017 May; 187():112-121. PubMed ID: 28454795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth and innovation in medical devices: a conversation with Stryker chairman John Brown. Interview by Lawton R. Burns.
    Brown J
    Health Aff (Millwood); 2007; 26(3):w436-44. PubMed ID: 17472967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving the drug selection and development process for combination devices.
    Hupcey MA; Ekins S
    Drug Discov Today; 2007 Oct; 12(19-20):844-52. PubMed ID: 17933686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary.
    Byrne RA; Serruys PW; Baumbach A; Escaned J; Fajadet J; James S; Joner M; Oktay S; Jüni P; Kastrati A; Sianos G; Stefanini GG; Wijns W; Windecker S
    Eur Heart J; 2015 Oct; 36(38):2608-20. PubMed ID: 26071600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries.
    Yoshida T; Sakata K; Nitta Y; Taguchi T; Kaku B; Katsuda S; Shimojima M; Gamou T; Nakahashi T; Konno T; Kawashiri MA; Yamagishi M; Hayashi K
    Heart Vessels; 2016 May; 31(5):635-42. PubMed ID: 25758470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fully bioresorbable drug-eluting coronary scaffolds: A review.
    Charpentier E; Barna A; Guillevin L; Juliard JM
    Arch Cardiovasc Dis; 2015; 108(6-7):385-97. PubMed ID: 26113479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current status of drug-eluting stents and drug-eluting balloons in patients with stable coronary artery disease--an expert consensus document of the Association for Percutaneous Cardiovascular Interventions and Polish Cardiac Society].
    Witkowski A; Opolski MP; Dudek D; Lesiak M; Legutko J; Wojakowski W; Ochała A; Maciejewski P; Deptuch T; Araszkiewicz A; Gil R; Grajek S; Poloński L;
    Kardiol Pol; 2011; 69 Suppl 1():1-38. PubMed ID: 22125234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.
    Giustino G; Harari R; Baber U; Sartori S; Stone GW; Leon MB; Windecker S; Serruys PW; Kastrati A; Von Birgelen C; Kimura T; Stefanini GG; Dangas GD; Wijns W; Steg PG; Morice MC; Camenzind E; Weisz G; Smits PC; Sorrentino S; Sharma M; Farhan S; Faggioni M; Kandzari D; Galatius S; Jeger RV; Valgimigli M; Itchhaporia D; Mehta L; Kim HS; Chieffo A; Mehran R
    JAMA Cardiol; 2017 Aug; 2(8):855-862. PubMed ID: 28658478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of biodegradable polymer versus durable polymer drug-eluting stents incorporating real-world evidence.
    Teng M; Zhao YJ; Khoo AL; Ananthakrishna R; Yeo TC; Lim BP; Chan MY; Loh JP
    Cardiovasc Ther; 2018 Oct; 36(5):e12442. PubMed ID: 29873191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future stent drug delivery systems.
    Caixeta A; Abizaid A; Aoki J; Dangas G; Mehran R
    Minerva Cardioangiol; 2008 Feb; 56(1):155-66. PubMed ID: 18432177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia.
    Noguchi A; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2022 May; 56(3):523-529. PubMed ID: 35181842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term clinical outcomes of overlapping heterogeneous drug-eluting stents compared with homogeneous drug-eluting stents.
    Her SH; Yoo KD; Park CS; Kim DB; Lee JM; Kim PJ; Kim HY; Chang K; Jeon DS; Chung WS; Seung KB; Kim JH
    Heart; 2011 Sep; 97(18):1501-6. PubMed ID: 21719556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.
    Arai H; Ouchi Y; Toba K; Endo T; Shimokado K; Tsubota K; Matsuo S; Mori H; Yumura W; Yokode M; Rakugi H; Ohshima S
    Geriatr Gerontol Int; 2015 Jun; 15(6):673-87. PubMed ID: 25656311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
    Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
    JACC Cardiovasc Interv; 2016 Feb; 9(3):271-277. PubMed ID: 26847118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of drug-eluting stents.
    Kukreja N; Onuma Y; Daemen J; Serruys PW
    Pharmacol Res; 2008 Mar; 57(3):171-80. PubMed ID: 18339557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials.
    Stefanini GG; Baber U; Windecker S; Morice MC; Sartori S; Leon MB; Stone GW; Serruys PW; Wijns W; Weisz G; Camenzind E; Steg PG; Smits PC; Kandzari D; Von Birgelen C; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Valgimigli M; Kastrati A; Chieffo A; Mehran R
    Lancet; 2013 Dec; 382(9908):1879-88. PubMed ID: 24007976
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.